BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-50@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Atea Pharmaceuticals\, Inc. — Bemnifosbuvir-Ruzasvir [De
 c 2026]
DESCRIPTION:Phase 3 primary completion: C-Forward: Efficacy and Safety of B
 EM/RZR vs SOF/VEL in Subjects With Chronic HCV.\nSource: https://clinicalt
 rials.gov/study/NCT07037277\nhttps://catalystbrief.girapphe.com/e/50?lang=
 en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/50?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
